ArticlePDF Available

'Hitting Highs at Rock Bottom': LSD Treatment for Alcoholism, 1950-1970



In the 1950s, researchers in the Canadian province of Saskatchewan began treating alcoholics with d-lysergic acid diethylamide (LSD) and achieved significant rates of recovery. Psychiatrists, including Humphry Osmond who coined the term ‘psychedelic’ while working in Saskatchewan, believed that the successful treatment of alcoholism with biochemical means would scientifically prove that the condition was a disease and not the result of a weak or immoral character. Initial experiments demonstrated unprecedented rates of abstinence among alcoholics treated with LSD. The approach gained support from the provincial government, local chapters of Alcoholics Anonymous and the Bureau of Alcoholism, all of which collaborated in a public campaign that supported LSD treatments. Although Alcoholics Anonymous endorsed psychedelic therapy, the Addictions Research Foundation did not. The leading Canadian authority on addictions disputed the findings in Saskatchewan and challenged these advocates of psychedelic treatments to conduct trials with proper controls. Despite subsequent efforts to demonstrate that the success of psychedelic therapy relied on both medical and non-medical factors, the treatment failed to satisfy current medical methodology, embodied in controlled trials. By the late 1960s, LSD had become a popular recreational drug and gained media attention for its association with counter cultural youth, social disobedience and anti-authoritarian attitudes. All this served further to erode support for its clinical status.
‘Hitting Highs at Rock Bottom’: LSD Treatment for
Alcoholism, 19501970
Erika Dyck*
Summary. In the 1950s, researchers in the Canadian province of Saskatchewan began treating alco-
holics with d-lysergic acid diethylamide (LSD) and achieved significant rates of recovery. Psychiatrists,
including Humphry Osmond who coined the term ‘psychedelic’ while working in Saskatchewan,
believed that the successful treatment of alcoholism with biochemical means would scientifically
prove that the condition was a disease and not the result of a weak or immoral character. Initial
experiments demonstrated unprecedented rates of abstinence among alcoholics treated with LSD.
The approach gained support from the provincial government, local chapters of Alcoholics Anon-
ymous and the Bureau of Alcoholism, all of which collaborated in a public campaign that supported
LSD treatments. Although Alcoholics Anonymous endorsed psychedelic therapy, the Addictions
Research Foundation did not. The leading Canadian authority on addictions disputed the findings
in Saskatchewan and challenged these advocates of psychedelic treatments to conduct trials with
proper controls. Despite subsequent efforts to demonstrate that the success of psychedelic
therapy relied on both medical and non-medical factors, the treatment failed to satisfy current
medical methodology, embodied in controlled trials. By the late 1960s, LSD had become a
popular recreational drug and gained media attention for its association with counter cultural
youth, social disobedience and anti-authoritarian attitudes. All this served further to erode
support for its clinical status.
Keywords: LSD; alcoholism; treatment; post-Second World War; Saskatchewan; psychiatry;
Humphry Osmond; psychedelic therapy
In the early 1950s, clinical researchers exploring the therapeutic value of the psychedelic
drug d-lysergic acid diethylamide (LSD) achieved intriguing results with subjects suffering
from alcoholism. Spiritual or transcendental experiences produced by LSD were a power-
ful adjunct to rehabilitative psychotherapy for alcoholics. They provided a profound and
chemically-induced awakening or enlightenment that often led to sobriety. This article
investigates LSD as a treatment for alcoholism. The increased focus on drug therapies
brought changes in treatment options and ushered in new theoretical explanations for
the causation of alcohol abuse as a disease.
The concept of alcohol addiction increasingly attracted medical attention in the first
half of the twentieth century. Alcoholism established itself as a medical problem rather
than a moral failing.
The concept of addiction or abuse as a disease was not a new
concept in the 1950s, but attention to ‘problem drinking’ entered a phase of renewed
*Department of History and Classics/Division of Studies for Medical Education, 2– 2 Tory Building, Univer-
sity of Alberta, Edmonton, Alberta, T6G 2H4, Canada. E-mail:
Conrad and Schneider 1992; Valverde 1997, pp. 251– 68; Dowbiggin 2000, pp. 37–69; Room 2003,
pp. 221– 34.
Social History of Medicine Vol. 19, No. 2 pp. 313–329
&The Author 2006. Published by Oxford University Press on behalf of the Society for the Social History of Medicine.
All rights reserved. DOI 10.1093/shm/hkl039
interest during this period.
In some ways, the history of the disease reveals more about
changing political and social attitudes towards drinking than medical innovation. LSD
treatments were introduced alongside an upsurge of interest in mitigating the conse-
quences of excessive alcohol consumption during a period of post-war reconstruction.
Historians agree that during the 1950s problem drinking, or alcoholism, moved into
the medical arena. They disagree, however, on the motivations for this transition.
Some scholars view the medicalisation of alcoholism as the result of pioneering
medical innovations in alcohol studies, especially those conducted by Yale University pro-
fessor E. M. Jellinek. According to these scholars, new clinical studies and medical
approaches offered compelling evidence that problem drinking had a genetic or biologi-
cal explanation and should thus be treated by medical professionals.
Other scholars have argued that, despite these clinical advances, the prime mover
behind medicalisation was not, in fact, medical. They claim that acknowledging alcohol-
ism as a medical disorder rather than a moral failing facilitated the expansion of state-
funded treatment centres, identifying the condition as a primarily political dilemma.
Governments reluctant to direct public funds towards a moral or social problem were
now faced with the prospect of including alcohol treatment centres in the state-
supported health system.
Yet other scholars maintain that commercial considerations
played the most significant role in changing perceptions of problem drinking. They
argue that the acceptance of the condition as a disease increased profits for the alcoholic
beverage industry, which could now more persuasively suggest that alcoholism only
affected specified individuals. Punitive prohibition policies would therefore be futile.
Each of these positions illustrates the multi-faceted process involved in identifying and
disseminating the idea of alcoholism as a medical disease. Historians disagree on how to
prioritise motivating factors. This case study maintains that a confluence of medical and
non-medical factors influenced the identification and acceptance of problem drinking as
a disease and these factors cannot be isolated from one another.
Alcoholism as a Biochemical Disease
The psychiatrist Humphry Osmond was one of the key figures in the development of LSD
treatments for alcoholism. Osmond was a Senior Registrar at the psychiatric unit at St
George’s Hospital in London, England in 1950, where he worked closely with his col-
league John Smythies and cultivated a keen interest in chemically induced reactions in
the human body. Smythies and Osmond examined the properties of mescaline, the
active agent in the peyote cactus. Nearly two years of research led them to conclude
that mescaline produced reactions in volunteers that resembled the symptoms of schizo-
phrenia, including hallucinations, delusions, disorganised thoughts and behaviour.
Further work suggested that mescaline’s chemical structure was remarkably similar to
adrenaline. These findings led to the theory that schizophrenia resulted from a
Term used by Heather and Robertson 1997.
Page 1988, p. 1098; Tracy and Acker (eds) 2004, pp. 61 –87; Heather and Robertson 1997, ch. 2.
Thom and Berridge 1995, p. 91.
Burnham 1993; Sournia (ed.) 1990, p. xv.
Smythies 2004, n. p. I am grateful to John Smythies for sharing his unpublished manuscript with me.
314 Erika Dyck
biochemical ‘imbalance’ in the sufferer. This tantalizing hypothesis captivated Osmond’s
interest for the next two decades and inspired him to embark on a variety of experiments.
Osmond and Smythies’ colleagues at St George’s Hospital were not particularly inter-
ested in their biochemical research, but Osmond was intent on continuing the work.
After responding to an advertisement in The Lancet for a deputy director of psychiatry
at a Canadian Mental Hospital in Weyburn, Saskatchewan, he and his family moved to
Canada in October 1951. In the prairie province of Saskatchewan he established a bio-
chemical research programme. Within a year of arriving in Weyburn, Osmond met
Abram Hoffer. Hoffer had grown up in a small farming community in Saskatchewan.
He had graduated from the provincial university in Saskatoon with a Bachelor of Sciences
degree in agricultural chemistry in 1937. Seven years later he graduated with a Ph.D. in
agriculture before beginning a medical degree the following year. In medical school he
developed a particular interest in psychiatry. On 1 July 1950, the Saskatchewan Depart-
ment of Public Health hired the recently graduated Hoffer to establish a provincial
research programme in psychiatry.
Hoffer and Osmond soon joined forces and began collaborating on their mutual
research interests in biochemical experimentation. Osmond’s curiosity about mescaline
soon introduced him to d-lysergic acid diethylamide (LSD), which, he discovered, pro-
duced similar reactions to those observed with mescaline. However, LSD was a much
more powerful drug. As in the case of mescaline, early trials with LSD, too, seemed to
substantiate their theory that mental illness had biochemical roots. During their initial
LSD experiments, Hoffer and Osmond hypothesised that the drug might possess thera-
peutic benefits. For example, experiments with volunteers demonstrated the drug’s enor-
mous capacity to bring individuals to new levels of self-awareness. Following an LSD
experience some people felt that they had gained a different perspective on their role
in community, family, or society in general. Some described this feeling as a new sense
of spirituality; others contended that the change was essentially philosophical. Hoffer
and Osmond wanted to know whether change of this type might have an effect on mod-
ifying an individual’s behaviour or habits. In 1953 they began introducing the drug to a
new set of subjects: diagnosed alcoholics. They wanted to test its curative effects on indi-
viduals for whom temperance reformers advocated the development of more will power
and self-actualisation. Perhaps, they reasoned, the LSD reaction would cultivate precisely
that kind of strength and insight.
The Drinking Society
Osmond reasoned that, given the growing social acceptance of drinking in the period
after the war, it would not be difficult to convince lay people that excessive drinking or
alcoholism, as a disease, constituted a meaningful concept. He acknowledged that
failed prohibition efforts in North America meant that a great number of individuals
now supported the idea of responsible drinking. Many people, historically and cross-
culturally, had demonstrated the capacity to enjoy alcohol consumption and incorporate
it into responsible social interactions. Thus, excessive drunkenness must display a lack of
Saskatchewan Archives Board (hereafter referred to as SAB), Correspondence, McKerracher, 20 April
1950, p. 1.
LSD Treatment for Alcoholism, 1950–1970 315
control on the part of the individual.
The problem, Osmond contended, was that medical
researchers had been preoccupied with gathering evidence proving that social factors
influenced the development of excessive drinking behaviour. Variables such as class,
gender, race and ethnicity had emerged from earlier studies as important indicators for
excessive drinking. But Osmond maintained that emphasis on socio-demographic
factors had produced much worthless information. For example, the observation that
Irish men drink more than Jewish men offered no prescriptive solution to the problem
of alcoholism. He suggested that ‘the forcible conversion of Irishmen to Judaism would
not commend itself much to either of those ancient and resilient people’.
Instead of con-
centrating on examining the social characteristics of problem drinkers from an external
vantage point, Osmond recommended exploring the social characteristics of what he
referred to as the ‘drinking society’.
Across North America, Osmond estimated that approximately a hundred million people
belonged to the drinking society, of whom roughly 5 per cent developed alcoholism.
suggested that this social group existed across linguistic, gender, class, race, and age cat-
egories and acquired their own distinctive culture and rituals, centred on drinking. Indi-
viduals who became alcoholics were—somewhat ironically—leaders or heroes within
this society. For example, Osmond stated that:
an alcoholic-to-be is liable to be admired early in his career; indeed he may even be
envied by members of the drinking society, his attainments may well receive appro-
bation and he will be invested with status and prestige. At this time his activities are
not considered rash or imprudent—quite the reverse. His drinking companions may
well feel a little wistful that they do not have a head like his and that their legs are
not hollow. It is unlikely that anyone rewarded in this manner by his peers will stop to
ponder the possible long-term consequences of what may seem to be a wonderful
According to Osmond, the escalation of acceptable drinking into excessive (problem)
drinking took place within a specific socio-cultural context, which excluded restraint.
Alcohol consumption and machismo existed as mutually reinforcing factors; excessive
drinking earned additional status. Jake Calder, director of Saskatchewan’s Bureau on
Alcoholism, agreed with Osmond and stated that intoxication had specific rewards for
young adult males because ‘it is considered to be a sign of masculinity and adulthood,
even though it is disapproved by many other elements of society’.
Similarly, Seldon
Bacon at Yale University recognised that the American frontier society valued an image
of masculinity, which, among much else, habitually included drinking.
While the
sober observer may have concluded that the leaders of the drinking society
exhibited a lack of control, the conventions of the drinking culture implied
the reverse: he who held his liquor demonstrated control, authority, and even
SAB, Osmond, ‘Notes on the Drinking Society’, 1967, p. 1.
SAB, Osmond ‘Notes on the Drinking Society’, p. 2.
SAB, Osmond ‘Notes on the Drinking Society’, p. 3.
SAB, ‘Spiritual Factors in the Recovery of Alcoholism’, p. 8.
Bacon 1958, pp. 55–64.
316 Erika Dyck
By envisioning a medical approach that adopted an empathetic perspective
and appreciation for the social context of the drinking society, Osmond championed a
disease model, accompanied by a treatment that acknowledged the nature of the drink-
ing society.
According to Hoffer, the idea of relating the LSD experience to alcoholism occurred to
him one evening while he and Osmond were at a conference in Ottawa in 1953. They had
arrived in the capital to address the Department of National Health and Welfare, but had
difficulty sleeping in the hotel the night before the meeting. So they decided to forgo rest
and spent the night in discussing contemporary challenges facing psychiatrists. Around
four in the morning they floated the idea that LSD experiences were remarkably similar
to descriptions of delirium tremens, or the effects of an alcoholic ‘hitting bottom’.
Hoffer recalled that the notion ‘seemed so bizarre that we laughed uproariously. But
when our laughter subsided, the question seemed less comical and we formed our
hypothesis .... Would a controlled LSD-produced delirium help alcoholics stay
Contemporary medical literature suggested that approximately 10 per cent
of delirium tremens (DTs) had fatal consequences for patients, but that DTs also might
mark a critical turning point in the course of the disease. If an LSD reaction could simulate
DTs, it might also help patients to overcome their desire to drink to excess. On returning
to Saskatchewan, Hoffer and Osmond decided to test this assumption.
Back on the prairies, Osmond treated one male and one female patient, each with a
single dose of 200 micrograms of LSD. Although he had already determined that
smaller amounts of the drug produced profound results—similar to DTs—Osmond
reasoned that alcoholic subjects required a larger dose.
Patients in the initial study
were chronic alcoholics in the Saskatchewan Mental Hospital in Weyburn. Following
the LSD treatment, the male patient stopped drinking and remained sober for at least
six months, at which point the follow-up study ended. The female patient continued
drinking after the experiment but stopped during the follow-up period. The results
were puzzling, and Osmond and Hoffer concluded this miniature experiment showed
that LSD might have a 50 per cent chance of helping alcoholics. Over the next decade,
they tested this hypothesis on over 700 patients and claimed that results were astonish-
ingly similar to those in the first experiment.
Despite the original contention that LSD simulated psychotic symptoms, the results of
the trials on alcoholics demonstrated that a ‘psychedelic’ or mind-manifesting experience
offered real therapeutic benefits.
Hoffer maintained that ‘from the first we considered
not the chemical, but the experience as a key factor in therapy—in fact, we used a sort of
psychotherapy made possible by the nature of the experience’.
This assertion
Ibid., pp. 1–10.
Hoffer 1967, p. 343.
Ibid., pp. 343–406.
Osmond, and others, studied the doses through self-experimentation before administering them to
patients. Clancy et al. 1954, pp. 147–53.
SAB, Osmond, ‘Notes on the Drinking Society’, p. 1. For published results, see Chwelos et al. 1959,
pp. 577– 90.
Osmond coined the term psychedelic in 1957 to mean mind-manifesting, or to bring to light.
Hoffer 1966, p. 19.
LSD Treatment for Alcoholism, 1950–1970 317
differentiated LSD treatment from other psychopharmacological therapies by enlarging the
definition of disease and treatment to include the more subjective area of experience.
model of alcoholism proposed in Saskatchewan differed from the contemporaneous
research undertaken by E. M. Jellinek at Yale, which did not take into account subjective
LSD was difficult to control and outcomes seemed uncertain, which made
several of Hoffer’s and Osmond’s colleagues reluctant to support their therapy. At the
heart of the enterprise lay a desire to produce an experience that deeply affected research
subjects, to the extent that they might change their behaviour. In Hoffer’s and Osmond’s
view, this approach not only presupposed a medical model of alcoholism as a disease,
but it also aimed at restoring self-control. Drugs alone constituted an insufficient thera-
peutic modality. Rather, Hoffer and Osmond argued that treatment must also re-establish
personal control. Because LSD acted upon the individual both chemically and psychologi-
cally, psychedelic therapy constituted the better option.
Although Hoffer and Osmond acknowledged that LSD produced highly individualised
results that made classification of reactions difficult, they recognised the need to identify
common trends to promote their therapy within the framework of mainstream psychia-
try. Their earlier biochemical research on schizophrenia supplied some of the theoretical
background for explaining the results of their trials with alcoholics. Accordingly, they ela-
borated a biochemical explanation based on their previous studies that demonstrated an
increased rate of adrenaline production in patients with schizophrenia.
Related research
on chronic alcoholics indicated comparable levels of adrenaline production, particularly
during delirium tremens. Thus Hoffer and Osmond hypothosised a biochemical cause
for alcoholism.
In 1955, psychiatrist Colin Smith conducted another LSD study in Saskatchewan, invol-
ving 24 alcoholics from the University Hospital in Saskatoon. Patients in this study had
been diagnosed with chronic alcoholism and had agreed to a two to four week stay at
the hospital. During the first part of their stay, Smith encouraged them to talk about
their drinking while he explained the objectives of the trial. Although previous research
indicated that LSD experiences varied widely from one individual to another, he made
an effort to prepare subjects for the kinds of responses to be expected from the drug.
An inventory of experiences demonstrated the strong likelihood that subjects would
encounter changes in sensory observation, including distortions in perception, disorienta-
tion, and sensory over-loading. In addition, Smith knew that patients often felt that LSD
affected perception of time.
These kinds of general observations provided patients with
some ideas about how the drug might affect them during and after the experiment.
In the final days of their stay, patients received a single dose of LSD ranging from 200 to
400 micrograms, or half a gram of mescaline.
The experiment took place in the
SAB, J. F. A. Calder, ‘Experience with New Drug’, (unpublished) 18 and 19 May 1960.
Mangini 1998, pp. 381–6.
Abramson (ed.) 1967, pp. 343–406.
SAB, ‘Inventory’, p. 2.
Researchers in British Columbia followed a similar approach but used even larger doses ranging from 400
mcg to 1500 mcg of LSD. They maintained that the higher doses were nonetheless minute when com-
pared with other drugs. For a discussion of these doses, see Smart et al. 1967, p. 91 and Abramson 1967,
p. vii.
318 Erika Dyck
hospital, but usually a patient spent the day in a private room or in a doctor’s office,
accompanied by a nurse and/or a psychiatrist. In the early trials, no concerted efforts
were made to create a stimulating environment, but as the trials progressed, stimuli
such as music, fresh cut flowers, paintings and other visual aids were added to intention-
ally create an environment with perceptual distractions.
Staff encouraged patients to
enjoy the experience and either talk to, or withdraw from, others in the room.
Approximately eight hours after consuming LSD, the experience began to recede and
patients returned to the ward where they might take a second drug to help them
sleep. The following day, subjects were encouraged to compose a written description
of their experience, without interference from hospital staff.
In Smith’s trial, patients remained in the hospital for a few days following treatment. He
strongly advised them to take up or renew their membership of Alcoholics Anonymous on
A follow-up for Smith’s trial ranged between three months and three years
and relied on the cooperation of family, friends, community organisations, employers,
and Alcoholics Anonymous. Interviews with patient contacts in the community, as well
as family members, allowed researchers to conduct assessments that went beyond the
clinical format. The final report from Smith’s study stated that none of the patients had
become worse. While twelve patients remained ‘unchanged’, six were stated to have
‘improved’ and the other six patients were described as ‘much improved’.
To qualify
as ‘much improved’, a patient needed to exhibit complete abstinence from alcohol for
the duration of the follow-up period.
This status applied to those demonstrating a
significant reduction in alcohol intake in combination with changes in lifestyle, including
more stable personal relationships and regular employment.
Alcoholics Anonymous
As Smith’s experiment illustrated, the trial involved the community at two levels. Local
participation was necessary for coordinating follow-up reports on the drinking habits
of patients. Conversely, community involvement generated support for medical research
and helped reduce political opposition to treating alcoholism in publicly funded treatment
centres. Actively involving non-alcoholic members of the community in the treatment
programme extended the medicalisation of alcoholism into public discourse surrounding
problem drinking. Medico-legal presentation of alcoholism as a masculine disease
This idea came from Al Hubbard who worked at the Hollywood Hospital in New Westminster, British
Columbia. Hubbard was well known to Hoffer, Osmond and other LSD researchers.
Smith 1958, pp. 406 –17. Before conducting this study, more research into appropriate doses confirmed
that alcoholics had a higher tolerance to psychedelic drugs than non-alcoholics. Throughout these
studies, researchers in Saskatchewan worked closely with local branches of Alcoholics Anonymous,
both to recruit volunteers and to improve treatment and follow-up care. Bill W. himself, founder of
Alcoholics Anonymous, became an advocate of Hoffer and Osmond’s therapies; Kurtz 1979,
pp. 138– 9.
Smith 1958, p. 411.
Follow-up periods varied widely. Ideally, patients were monitored for a minimum of two years after treat-
ment. Some patients moved out of the community and did not remain in contact with either the research
team or Alcoholics Anonymous, which made extended follow-up problematic. Conversely, some patients
maintained contact for several years beyond the two-year period.
Smith 1958, p. 408.
LSD Treatment for Alcoholism, 1950–1970 319
changed popular perceptions about whether those suffering from the condition should
be subjected to medical treatment or legal sanction.
This medical–communal alliance strengthened non-medical organisations in their
attempts to help alcoholics. Alcoholics Anonymous (AA) had been founded in 1935 as
a body dedicated to assisting individuals with an ‘honest desire’ to stop drinking. By
1941, AA boasted over 8,000 members in chapters across North America and it
quickly surpassed medical intervention in reports of the fight against excessive drinking.
The principles of AA were not grounded in medical expertise but relied on fraternal
support offered by members who shared experiences with one another. This approach
created an alternative non-drinking society, which shaped its own rules to the needs of
problem drinkers. The collegial function of the organisation continued to provide recover-
ing alcoholics with a social outlet—an important aspect, as several members had high-
lighted the central role of shared activities surrounding drinking. By providing
peer-evaluated and empathetic therapy, AA had by the late 1940s become the most
effective form of treatment and promised a 50 to 60 per cent chance of recovery.
This rate exceeded the medical rate, based on aversion therapy, or the use of chemical
substances to suppress the desire to drink, by between 10 and 30 per cent.
In addition to providing social space and peer support for individuals struggling with
excessive drinking, AA adopted a ‘twelve-step’ tradition or programme for combating
alcoholism. Part of the process involved early recognition of the ultimate authority of
Co-founder of AA, Bill W., believed this stage as critical for beginning the recovery
process. It was ‘spiritual’ or religious and reminded the individual that he or she was
neither alone, nor wholly self-sufficient. Instilling these values became an integral part
of breaking with the patterns and conventions of membership of a drinking society.
Bill W. recalled that ‘it was only a matter of being willing to believe in a power greater
than myself. Nothing more was required of me to make my beginning.’
Arriving at
this perspective was often the most difficult obstacle for individuals trying to overcome
a desire to drink, although more individuals achieved spiritual epiphany after experiencing
delirium tremens. For many alcoholics, however, DTs proved fatal. As a consequence, AA
devised strategies of bringing members to a state of ‘spirituality’ before going through
delirium tremens.
The LSD treatments being developed in Saskatchewan in the 1950s offered a chemi-
cally induced experience that often generated a sense of spirituality. Subjects frequently
described their reactions in spiritual terms and claimed that the experience had an over-
powering effect on self-perception. The frequency of these kinds of responses led some
researchers to believe that LSD was in fact a psychoactive substance capable of creating
this specific kind of reaction. In the late 1950s, Bill W. himself experimented with LSD.
Alcoholics Anonymous 1955, p. xviii; W. 1994, pp. 259– 62.
W. 1994, p. 571.
The most commonly cited alternative treatment was antabuse, which produced extreme nausea when
individuals drank even small amounts of alcohol. It acted as a form of aversion therapy; Conrad and
Schneider 1980, p. 74; Barrera, Osinski and Davidoff 1994, pp. 263– 7.
Step Two reads: ‘For our Group purpose there is but one ultimate authority—a loving God as He may
express Himself in our Group conscience’; Alcoholics Anonymous 1955, pp. 564–5.
Ibid., p. 12.
320 Erika Dyck
Although he was reluctant to support the use of drugs that might compromise sobriety,
the promise of spiritual experience intrigued him.
After a few sessions, Bill W. discon-
tinued experimentation because of his role as the only surviving co-founder of an organ-
isation devoted to sobriety. Nevertheless, he continued to correspond with Hoffer and
Osmond in Saskatchewan and quietly supported their efforts to introduce ‘spirituality’
into medical discourses on alcoholism.
Saskatchewan’s director for the Bureau on Alcoholism, Jake Calder, also believed that
LSD offered an effective form of medical treatment because it addressed the spiritual
needs of the alcoholic and that these had been excluded from medical models.
explained that, on the one hand, AA benefited from medical research into the disease
since it provided scientific evidence that undermined arguments about the inherent
moral weakness of alcoholics. On the other hand, most medical theories betrayed the
experience of alcoholism by ignoring spiritual and social aspects of the disease as it
was actually experienced by the patient.
By working closely with AA, and developing
a clinical approach that paid attention to the experience of the addiction, Calder
endorsed the research programme in Saskatchewan as the best available medical
Following Smith’s original trial in 1958, the Saskatchewan researchers prepared a scien-
tific account of the immediate results of the clinical trials and the lay perspectives
collected during the follow-up period. Contrary to their earlier hypothesis that LSD pro-
duced a reaction similar to delirium tremens, they now suggested that the drug caused
‘an upsurge of previously repressed material’, or, in some cases, ‘the effects resembled
the state of religious conversion’.
However, they maintained that psychedelic treatment
continued to rely on a biochemical understanding of alcoholism as a disease. In addition,
intangible and often indescribable experiences left patients and psychiatrists alike strug-
gling to find appropriate language to explain the effects of the drug.
A relatively typical example of an alcoholic patient’s reaction was included in a psychia-
tric report, which stated that:
he had a momentary oneness with God. Had a vision while lying [down] with eyes
closed of a spiral staircase with himself talking to another person. This appeared to
have great meaning to him. ... He seems to have gained some insight and under-
standing of himself.
This reaction matched the ideals of AA by stimulating an overtly ‘spiritual’ experience and
it persuaded the Saskatchewan group to continue conducting LSD trials with alcoholics
who expressed a desire to stop drinking. Linking material of this kind to AA principles
Lobdell 2004, p. 250.
SAB, Correspondence with Calder, speech from Calder, ‘Spiritual Factors in the Recovery of Alcoholism’,
June 1960, p. 1.
SAB, Correspondence with Calder, speech from Calder, ‘Spiritual Factors in the Recovery of Alcoholism’,
June 1960, p. 3.
Smith 1959, p. 293.
SAB, Clinical Files, LSD Trials, ‘anonymous’. Patients’ names have been removed by the author to main-
tain confidentiality.
LSD Treatment for Alcoholism, 1950–1970 321
also helped play down psychoanalytical overtones by couching the explanation in overtly
experiential terms.
Because of the intensely personal and subjective experiences generated by LSD treat-
ment, classifying and evaluating on the part of patients presented a tremendous chal-
lenge. Individuals underwent a trial in the presence of a doctor or nurse who made
observations throughout the experiment. Observers then encouraged subjects to write
their own report on the experience within a few days. While witnesses to experiments
commented on observed behaviour and statements, subjects regularly complained that
they had difficulty in describing experiences. The distortion of sensory perceptions and
overwhelming, often racing, flows of feelings and ideas frequently left subjects struggling
to find words to express what had occurred.
Despite these challenges, patients offered personal statements after the trial that con-
tributed an invaluable perspective. Transcripts and patients’ reports from the University
Hospital in Saskatoon from 1958 to 1966 contained several examples of patients’ experi-
ences, in their own words.
In each of the 216 cases, patients completed a consent form,
and a nurse attendant attached a transcript that recorded the chronology of events and
the times at which empirically observable reactions took place. In a majority of cases, a
doctor’s report accompanied the trial docket; quite often the patient submitted a descrip-
tion in his or her own writing.
Anonymous excerpts expressed profundity of response.
The following description of a subject’s spiritual reaction, written (or recorded) the day
after treatment needs to be quoted at length adequately to convey the individual’s
How can I explain the face, vile, repulsive and scaly, that I took by the hand into the
depth of hell from whence it came and then gently removed that scaly thing from
the face and took it by the hand up up into the light and saw the face in all its
God given beauty, so much beauty that the pot could not hold it, but it could not
spill over. It seemed that my head and shoulders and hips down [there] were separ-
ated and my stomach was the battleground between good and evil. ... I finally
talked to [the doctor] who seemed to have no trouble understanding the things I
was describing to him and yet can not put on paper. It is a living thing I feel and I
wish I were an artist and could paint it or put it to music or verse for the world to
share. It seems to be a feeling that only someone that has seen the scale of all
emotions, through LSD or alcohol can even come close to knowing or believing
even in the most fantastic things you try to convey to them. It is a wonderful
feeling of the choice to go up or down. I chose to go up and feel clean fresh and
Patients’ perspectives come from an examination of reports and letters contained in SAB, Hallucino-
Subjects’ reports were often handwritten. Some were later typed. Sometimes subjects did not immedi-
ately submit a report, but wrote a letter to the presiding psychiatrist weeks or months later. In these
cases, the letters were not always transferred to the original file, but appeared in correspondence
files. It is therefore difficult to determine the precise number of individuals who offered personal
SAB, Hallucinogens—Patients ‘Subject’s Report’, anonymous subject report, p. 1.
322 Erika Dyck
Smith categorised this particular LSD experience as a classical psychedelic reaction. The
patient had a ‘spiritual’ experience, forcing himself to contend with forces of ‘good’
and ‘evil’ and emerged from the episode feeling confident and changed. Although
Smith required further information from follow-up studies before ascertaining whether
the treatment had been successful, he expected this patient to do well because of his
‘spiritual’ reaction. Although Smith considered a psychedelic reaction the most effective
for attaining sobriety, he also found that most patients reached new levels of self-
awareness even without having an overtly ‘spiritual’ experience. The latter could only
be ratified through consultation or after interpreting a patient’s report.
Patients’ own descriptions of their experiences often revealed insights that were nearly
impossible for observers to appreciate. Most observers had taken the drug themselves—
meaning that they could ‘understand’ the effects, but did not necessarily appreciate the
ways in which the reaction affected particular behaviour in each individual case. Nurses’
reports portrayed the challenge of recording a highly subjective experience when physical
reactions did not necessarily match emotional or psychological impressions. Yet psychia-
trists instructed nurses to compose reports based on observable changes. Often these
reports conflicted with reflections submitted by patients. For example, nurses sometimes
documented a patient’s withdrawal from a conversation or a marked desire to do nothing
and withdraw from the experimental setting. At such times, observers’ reports sometimes
questioned whether the drug had a major effect.
Thus, patients’ reports provided a revealing perspective on the effects of LSD and could
substantially enhance evaluation available through conventional means. For example, the
patient’s report describing the above experience claimed that the period of withdrawal
was in fact a moment of intense personal revelation. Another responded to the nurse’s
prompts to discuss his reasons for seeking therapy and responded: ‘I cannot look into
the past. Disgusted with myself. I am always scared of something. I want to be some-
The next day, however, the same patient stated: ‘In answer to why I fear
people, I found that I fear myself and my ability to do things right. In order to overcome
this fear I found I had to look inward to myself to conquer, instead of outside myself.’
He claimed that his arrival at this conclusion occurred during the LSD trial but that he had
been unable to express himself until the following day. These kinds of reflections under-
scored the importance of encouraging patients to provide their own impressions of trials
so that psychiatrists could adequately assess the value of the LSD experience. It also
suggested a pressing need for follow-up consultation.
A minority of cases in this trial in Saskatoon revealed evidence of an experience that
psychiatrists categorised as negative. Hoffer and others reasoned that the low rate of
negative reactions was, in large measure, due to the strict screening measures they
employed. Despite these precautions, there were negative responses to the drug. One
patient described his experience and said, ‘there are some worms. They’re nodding at
me. Am I dying? I must be dying because they’re eating my flesh. They’re gone now. I
can’t move. Am I dead?’.
The nurse-observer documented these words during the
SAB, Hallucinogens—Patients ‘Subject’s Report’, nurse’s report, p. 2.
SAB, Hallucinogens—Patients’ ‘Subject’s Report’, nurse’s report, n.p.
LSD Treatment for Alcoholism, 1950–1970 323
trial and because of their terrifying nature, the doctor terminated the reaction by giving
the patient a dose of niacin.
Interestingly, this individual later contended that despite
the frightening nature of his experiences he had been reassured by the presence of empa-
thetic staff. He remained confident that the drug produced his hallucinations and that the
worms and associated feelings existed ‘outside’ reality.
The variety of LSD reactions observed in hundreds of trials contributed to a growing
inventory of data on the experience. Coupled with self-experimentation, the Saskatche-
wan psychiatric research programme prepared some conclusions on these observations in
the early 1960s. One of the fundamental findings on psychedelic drugs illustrated
that they had the capacity to produce a ‘transcendental feeling of being united with
the world’.
The trials highlighted the importance of using LSD to cultivate a mind-
manifesting experience that led to personal insight, transcendence, or ‘spiritual’ enlight-
enment. Furthermore, while the drug triggered the reaction, the experience itself was
believed to yield the therapeutic benefits.
While public support for the treatment continued to grow in Saskatchewan, theories
underpinning psychedelic therapy came under attack from members of the medical com-
munity unwilling to support a methodological approach that mixed medical and socio-
psychological, even ‘spiritual’, models of addiction. Elsewhere, medical researchers
raised questions about the use of selection criteria, with some suspecting that alcoholism
could not be treated with any chemical substance at all, and, others still, challenging the
Saskatchewan group to repeat their results using a variety of controlled trials.
The leading organisation for drug and alcohol research in Canada, the Addictions
Research Foundation (ARF) in Toronto, weighed into the debates with its own set of
LSD studies. In a series of publications in the Quarterly Journal for Studies on Alcohol,
ARF researchers Reginald Smart and Thomas Storm criticised the Saskatchewan LSD
treatments for their lack of proper scientific methodology. The ARF contended that the
results presented misleading conclusions because investigators had not employed appro-
priate controls isolating the reaction of the drug from other influences. In particular, their
criticism focused on blatant disregard for environmental influences that could have
affected the capacity to produce an objective assessment of the drug’s effects. According
to Smart and Storm, reports claiming that LSD helped alcoholics overcome their problem
drinking presented misinformation about the efficacy of the drug. Until medical research-
ers conducted trials that controlled for environmental influences and isolated the reaction
of the drug itself, the ARF recommended the discontinuation of publications endorsing
psychedelic treatment.
In 1962, psychiatrist Sven Jensen, working in Weyburn, Saskatchewan, accepted this
challenge and published the first controlled trial on LSD treatment for alcoholism.
Jensen relied on three pools of subjects for treatment: one group of alcoholics took
LSD at the end of a hospital stay (usually lasting a few weeks); the second received
group therapy; and Jensen’s colleagues at Weyburn treated the third group with their
Analogous biochemical research suggested that niacin terminates the LSD reaction because it slows
adrenalin production. The method itself was recommended in Blewett and Chwelos 1959, ch. 7.
SAB, Hallucinogens—Patients ‘Subject’s Report’, subject’s report, n.p.
SAB, Gustav R. Schmiege, ‘The Current Status of LSD as a Therapeutic Tool’, (unpublished), p. 5.
324 Erika Dyck
own standard approaches, excluding psychedelic therapy.
In his two-year study, invol-
ving follow-up periods of 6 to 18 months, The results of the study demonstrated that 38
of the 58 patients given LSD remained abstinent throughout the follow-up period. These
numbers conveyed greater significance when compared with the second group. Among
those patients receiving nothing other than group therapy, only 7 of the 38 involved in
the trial remained abstinent. Even those figures, however, showed greater promise
than the results from the group treated by Jensen’s colleagues by other means; in this
group only 4 out of 35 patients stopped drinking.
Jensen published his study in the Quarterly Journal for Studies on Alcohol, and defined
the control mechanism in terms of the comparative component of the trial. He main-
tained that this exercise underscored the superiority of LSD treatment over the other
two methods. Moreover, this kind of controlled trial did not attempt to isolate the reac-
tion of the drug; a situation that empathetic researchers recognised increased feelings of
fear and paranoia in subjects while decreasing the probability of a beneficial psychedelic
reaction. Jensen’s comparative study allowed observers to retain the emphasis on moni-
toring complex subjective experiences rather than empirically observable reactions.
The ARF countered with its own trials. Researchers Reginald Smart, Thomas Storm,
William Baker and Lionel Solursh designed an experimental environment that isolated
the effects of the drug before analysing its efficacy. They administered LSD to subjects
and subsequently blindfolded them and/or employed physical restraints to restrict move-
ment. They instructed observers not to interact with the subject, creating a research
design aimed to minimise the influence of all factors except the drug itself. This approach
sought more adequately to ascertain whether the drug offered genuine benefits, or
whether the perceived advantages merely inspired clinical enthusiasm that corrupted
the real outcome. Subjects used in the ARF study showed some improvement, but,
overall, the results from this study demonstrated that LSD did not produce results analo-
gous to those claimed by the Saskatchewan group.
Conclusions from the ARF trial indi-
cated the ineffectiveness of LSD when measured under controlled circumstances. Given
the authority vested in this form of methodology, the ARF study represented damaging
The psychedelic investigators in Saskatchewan responded by arguing that the research
design itself functioned as a contributing factor to the poor results accumulated by the
ARF. The controls applied in the latter study, they argued, facilitated more frightening
reactions in patients by reducing the comfort level and raising apprehensions about
the trial. Their own personal and clinical experience with the drug strongly indicated
Jensen 1962, p. 4. Earlier attempts to measure the efficacy of LSD treatment in blind trials were aban-
doned after determining that reactions to the drug were too powerful to go undetected. Group
therapy involved regular psychotherapy sessions in a group setting; the other methods involved
one-on-one psychotherapy with psychiatrists, and milieu therapy, which involved in-patient treatment
and a combination of one-on-one psychotherapy sessions with one of Jensen’s colleagues, in combi-
nation with hospitalisation.
Jensen 1962, p. 5.
Smart et al. 1967, pp. 351–3; Smart et al. (eds) 1966, pp. 469 –82; Kurland et al. 1970, pp. 83 –94. The
latter authors describe the method used by Smart et al. as part of their attempt to isolate the drug
LSD Treatment for Alcoholism, 1950–1970 325
that environment had a significant effect on results. While they disagreed over which
influence had the more significant effect—environment or drug—they insisted that
both demanded consideration. By placing controls on this important influence, according
to Hoffer and Osmond, the ARF study failed to investigate the subject’s experience but
merely measured the existence of a reaction, which did not provide useful information
either to observer or subject.
A number of clinical studies from outside Canada supported the Saskatchewan group’s
fundamental contention that the psychedelic treatment pointed clinicians towards a
more sophisticated understanding of alcoholism and its treatment. A Danish study
published in 1962 argued that the effects of LSD produced fear and anxiety in patients,
which scared them into sobriety.
This article did not support the biochemical
perspective; in fact it recommended expending additional research energy on investi-
gating the psychological and ‘spiritual’ characteristics of mental illnesses. In 1966, a
Czechoslovakian study reported ‘good’ results with LSD treatment for personality
Although these publications did not directly confirm Jensen’s statistics,
they continued to reinforce the importance of exploring the kinds of reactions elicited
by psychedelic approaches.
By the end of the decade, supporters of these therapies attempted to construct
controlled experiments that would satisfy the growing professional commitment to
controlled-trial methodology.
On-going debate in medical journals underlined the
necessity of evaluating subjective reactions in drug experiments. Rather than regard
the psychedelic approach as unscientific, such articles insisted that a more nuanced evalu-
ation of the effects of drugs deserved attention from the medical profession.
Despite a growing range of perspectives supporting the extension of medical discourse
into the subjective realm of experience, the contemporary explosion of pharmaceutical
treatments increasingly relied on objective measures as a mark of modern
medico-scientific methodology. LSD emerged at the same time as the discovery and syn-
thesis of many of these chemical substances, but psychedelic drugs engaged clinical
investigators in methodological debates about the authority of the controlled trial. As
psychedelic practitioners continued to emphasise a philosophical agenda, their approach
moved closer to the edge of mainstream clinical research. Meanwhile, other psychophar-
macological substances, such as anti-psychotic and anti-depressant medications,
assumed a more typical image of psychopharmacological efficacy. In contrast to LSD,
these drugs flourished in controlled trials in which they repeatedly demonstrated their
capacity to reduce symptoms. Success, however, also represented the triumph of a
particular methodological approach that solidified specific standards for empiricism in
psychiatric discourse.
Psychedelic psychiatrists felt that conventional drug treatments, which required
extended periods of compliance, did not address issues of personal control but created
Hertz 1962, pp. 103–8.
Hausner and Dolez
ˇal 1966, pp. 87–95.
Hollister, Shelton and Krieger 1969, pp. 58– 63; Denson and Sydiaha 1970, pp. 443– 5.
326 Erika Dyck
another kind of dependence. LSD treatment, by contrast, offered one intense therapy
session that promised to restore control to the patient. Hoffer and Osmond reasoned
that this approach demonstrated confidence in the biochemical model, but their endorse-
ment of this method also implied a desire for further consideration of the culmination of
non-medical factors in therapy. The intensity of the single experience approach appealed
to patients as an appropriate method for treating a predominantly male disease, a disease
that allegedly developed out of an unhealthy obsession with displaying machismo. The
restoration of self-control generated by LSD treatment increased optimism that alcohol-
ism would not irreparably damage communities and families.
Although by the mid-1960s, LSD, or ‘acid’, had gained popular recognition as a street
drug, and one that would later become synonymous with the counter-culture of that
decade, in Saskatchewan in the 1950s it played a prominent role in reconstructing alco-
holism as a disease. The growing public perception of drunkenness as a physiological con-
dition reinforced the need for medical attention and, moreover, redefined problem
drinking behaviour as something that could be cured. LSD treatment not only supported
medical models of alcoholism but also had a strong appeal for policy-makers, Alcoholics
Anonymous and the lay public to recognise alcoholism as a condition with cultural and
medical implications for identification and treatment.
Financial assistance from the Social Sciences and Humanities Research Council of Canada
helped to fund this research. This article benefited from the generous advice of two anon-
ymous reviewers, David Wright, and participants of the International Conference on
Drugs and Alchohol in History who provided feedback on an earlier version of this
paper, particularly Robin Room and David Courtwright. I am deeply indebted to Jennifer
Keelan for her encouragement.
Primary sources
Saskatchewan Archives Board, A207, AII, Box 75; AII, 108; AII. V. (patients); AIII (correspondence),
194.a; AIII, 229.a; II.A., 108; XVII (clinical files); Box 37, 233-A.
Smythies J. 2004, excerpts from unpublished manuscript, no page numbers (electronic correspon-
dence with author).
Secondary sources
Abramson H. A. (ed.) 1967, The Use of LSD in Psychotherapy and Alcoholism, Indianapolis:
Alcoholics Anonymous 1955, Alcoholics Anonymous: The Story of How Many Thousands of Men
and Women Have Recovered from Alcoholism, New York: Alcoholics Anonymous Publishing, Inc.
Bacon S. 1958, ‘Alcoholics Do Not Drink’, Annals of American Academy of Political and Social
Science, 315, 55–64.
Barrera S. E., Osinski W. A. and Davidoff E. 1994, ‘The Use of Antabuse (tetraethylthiuramdisulphide)
in Chronic Alcoholics [July 1950]’, American Journal of Psychiatry, 151, 6, Sesquicentennial
Supplement, 263– 7.
Blewett D. C. and Chwelos N. 1959, Handbook for the Therapeutic Use of Lysergic Acid
Diethylamide-25, Individual and Group Procedures, Regina, Saskatchewan.
LSD Treatment for Alcoholism, 1950–1970 327
Burnham J. C. 1993, Bad Habits: Drinking, Smoking, Taking Drugs, Gambling, Sexual Misbehavior,
and Swearing in American History, New York: New York University Press.
Carson M. 1992, ‘Domestic Discontents: Feminist re-evaluations of psychiatry, women, and the
family’, Canadian Review of American Studies, special issue, pt. 2, 171– 92.
Cheever S. 2004, My Name is Bill. Bill Wilson: His Life and the Creation of Alcoholics Anonymous,
New York: Simon and Schuster.
Chwelos N., Blewett D. C., Smith C. and Hoffer A. 1959, ‘Use of d-lysergic diethylamide in the treat-
ment of alcoholism’, Quarterly Journal of Studies of Alcohol, 20, 577– 90.
Clancy J., Hoffer A., Lucy J., Osmond H., Smythies J. and Stefaniuk B. 1954, ‘Design and Planning in
Psychiatric Research as illustrated by the Weyburn chronic nucleotide project’, Bulletin of the
Menninger Clinic, 18, 4, 147–53.
Conrad P. and Schneider J. 1992 [1980], Deviance and Medicalization: From Badness to Sickness,
Philadelphia: Temple University Press.
Denson R. and Sydiaha D. 1970, ‘A Controlled Study of LSD Treatment in Alcoholism and Neurosis’,
British Journal of Psychiatry, 115, 443–5.
Dowbiggin I. 2000, ‘Delusional Diagnosis? The History of Paranoia as a Disease Concept in the
Modern Era’, History of Psychiatry, 11, 37– 69.
Feldberg G., Ladd-Taylor M., Li A. and McPherson K. (eds) 2003, Women, Health, and Nation,
Montreal: McGill-Queens’ University Press.
Hausner M. and Dolez
ˇal V. 1966, ‘Follow-up Studies in Group and Individual LSD Psychotherapy’,
(PRAHA) Active Nerve Supplement, 8, 87–95.
Heather N. and Robertson I. 1997, Problem Drinking, 3rd edition, Oxford: Oxford University Press.
Hertz M. 1962, ‘Observations and Impressions from a Year’s Work with LSD’, Nordisk Psykiatrik Tids-
skrift, 16, 103– 8.
Hoffer A. 1966, ‘Treatment of Alcoholism Using LSD as the Main Variable’, Prisma,n.p.
Hoffer A. 1967, ‘A Program for the Treatment of Alcoholism: LSD, Malvaria and Nicotinic Acid’, in
Abramson H. (ed.), The Use of LSD in Psychotherapy and Alcoholism, Indianapolis: Bobbs-Merrill,
Hollister L. E., Shelton J. and Krieger G. 1969, ‘A Controlled Comparison of Lysergic Acid
Diethylamide (LSD) and Dextroamphetamine in Alcoholics’, American Journal of Psychiatry, 125,
10, 58–63.
Jensen S. 1962, ‘A Treatment Program for Alcoholics in a Mental Hospital’, Quarterly Journal of
Studies on Alcohol, 23, 315–20.
Kurland A., Savage C., Pahnke W. N., Grof S. and Olsson J. E. 1970, ‘Pharmakopsychiatrie
Neuro-psychopharmakologie’, Advances in Theoretical and Clinical Research,4,2,8394.
Kurtz E. 1979, AA: The Story or Not-God. A History of Alcoholics Anonymous, Centre City, Minne-
sota: Hazelden Educational Services.
Lobdell J. C. 2004, This Strange Illness: Alcoholism and Bill W., New York: Aldine de Gruyter.
Lunbeck E. 1994, The Psychiatric Persuasion: Knowledge, Gender, and Power in Modern America,
Princeton: Princeton University Press.
Mangini M. 1998, ‘Treatment of Alcoholism Using Psychedelic Drugs: A Review of the Program of
Research’, Journal of Psychoactive Drugs, 30, 4, 381– 418.
Page P. B. 1988, ‘The Origins of Alcohol Studies: E. M. Jellinek and the documentation of the alcohol
research literature’, British Journal of Addiction, 83, 1095– 103.
Prestwich P. E. 2003, ‘Family Strategies and Medical Power: “Voluntary” Committal in a Parisian
Asylum, 1876–1914’, in Wright D. and Porter R. (eds), The Confinement of the Insane: Inter-
national Perspectives, 1800– 1965, Cambridge: Cambridge University Press, 76– 99.
Room R. 2003, ‘The Cultural Framing of Addiction’, Janus Head, 6, 2, 221– 34.
Rotskoff L. 2002, Love on the Rocks: Men, Women, and Alcohol in Post-World War II America,
Chapel Hill: University of North Carolina Press.
Showalter E. 1985, The Female Malady: Women, Madness, and English Culture, 1830–1980,
New York: Pantheon Books.
328 Erika Dyck
Smart R. G., Storm T., Baker E. F. and Solursh L. 1966, ‘A Controlled Trial of Lysergide in the Treatment
of Alcoholism: The Effects on Drinking Behaviour’, Quarterly Journal of Studies of Alcohol, 27,
Smart R. G., Storm T., Baker E. F. and Solursh L. (eds) 1969, Lysergic Acid Diethylamide (LSD) in the
Treatment of Alcoholism: An Investigation of its Effects on Drinking Behavior, Personality Structure
and Social Functioning, Toronto: University of Toronto Press.
Smith C. 1958, ‘A New Adjunct to the Treatment of Alcoholism: The Hallucinogenic Drugs’,
Quarterly Journal for the Studies on Alcohol, 19, 406 –17.
Smith C. 1959, ‘Some Reflections on the Possible Therapeutic Effects of the Hallucinogens: With
Special Reference to Alcoholism’, Quarterly Journal for Studies on Alcohol, 20, 293.
Sournia J. C. 1990, A History of Alcoholism, Cambridge: Cambridge University Press.
Thom B. and Berridge V. 1995, ‘“Special Units for Common Problems”: The Birth of Alcohol
Treatments in England’, Social History of Medicine, 8, 75 –93.
Tracy S. and Acker C. J. (eds) 2004, Altering American Consciousness: The History of Alcohol and
Drug Use in the United States, 1800 –2000, Boston: University of Massachusetts Press.
Valverde M. 1997, ‘“Slavery from within”: The Invention of Alcoholism and the Question of Free
Will’, Social History, 22, 251– 68.
William W. 1994 [1949], ‘The Society of Alcoholics Anonymous’, American Journal of Psychiatry,
151, 6, Sesquicentennial Supplement, 259–62.
LSD Treatment for Alcoholism, 1950–1970 329
... The term "psychedelic" was coined by Humphrey Osmond in 1957 through conversations with the famous writer Aldous Huxley (Dyck, 2006). Drawing on the Greek words "psyche" (for mind or soul) and "deloun" (for show) it is now often translated as "mind-manifesting". ...
... Growing research interest on psychedelics has led to an accumulation of evidence in recent years showing their extensive potential to actively support health outcomes (for reviews see dos Johnson & Griffiths, 2017;Johnson et al., 2019). These include considerable treatment potential for smoking (Garcia-Romeu et al., 2015) and alcoholism (Bogenschutz et al., 2015;Dyck, 2006;Hoffer, 1967) as well as the treatment of cluster headaches (Sewell, Halpern, & Pope, 2006), thus contributing to physical wellbeing. Besides earlier, mixed results (e.g. ...
Full-text available
The achievement of sustainable prosperity requires the enhancement of human wellbeing alongside increased care for the environment. In recent years, much has been written on the role of different mental states and their potential to influence our way of thinking and, perhaps more importantly, the way we act. In this working paper, we explore the emerging potential of a type of mental state known as Self-Transcendent Experiences (STEs) to deliver beneficial effects on human wellbeing and sustainable attitudes and behaviours. Self-transcendent experiences can be facilitated by experiences of flow, awe and meditation, as well as psychedelic experiences. Some of these experiences can occur naturally, through sometimes unexpected encounters with nature or during immersion in every-day activities that one intrinsically enjoys, as well as through more intentional practices such as meditation or the use of psychedelics. We demonstrate how each of the four alternative types of STEs share some similar neurological underpinnings and review their links to improvements in human wellbeing and sustainable attitudes and behaviours. We also highlight potential risks across the different varieties of STEs and consider factors that need to be considered if they are to be employed as a practical means of supporting sustainable prosperity.
... Drawing on the Greek words "psyche" (for mind or soul) and "deloun" (for show), the term 'psychedelic' is now often translated as "mind-manifesting" (Dyck, 2006). Psychedelic substances are broadly divided into classic psychedelics and non-classic psychedelics. ...
... Growing research interest on psychedelics has led to an accumulation of evidence in recent years showing their potential to actively support human health outcomes (dos Santos et al., 2016;Johnson and Griffiths, 2017;Johnson et al., 2019;Raison et al., 2022). Psychedelic substances have been shown to have treatment potential for physical health problems such as alcoholism (Hoffer, 1967;Dyck, 2006;Bogenschutz et al., 2015) and cluster headaches (Sewell et al., 2006) as well as mental health problems such as depression, anxiety, addiction, obsessive-compulsive disorder and anorexia (Bogenschutz et al., 2015;dos Santos et al., 2016;Patra, 2016;Ross et al., 2016;Sanches et al., 2016;Roseman et al., 2018), among others. Notably, this field is still in its infancy and more research is required to consolidate findings. ...
Full-text available
In recent years, much has been written on the role of different mental states and their potential to influence our way of thinking and, perhaps more importantly, the way we act. With the recent acceleration of environmental and mental health issues, alongside the limited effectiveness of existing interventions, an exploration of new approaches to deliver transformative change is required. We therefore explore the emerging potential of a type of mental state known as self-transcendent experiences (STEs) as a driver of ecological wellbeing. We focus on four types of STEs: those facilitated by experiences of flow, awe, and mindfulness, as well as by psychedelic-induced experiences. Some of these experiences can occur naturally, through sometimes unexpected encounters with nature or during immersion in everyday activities that one intrinsically enjoys, as well as through more intentional practices such as meditation or the administration of psychedelics in controlled, legal settings. We explore the evidence base linking each of the four types of STE to ecological wellbeing before proposing potential hypotheses to be tested to understand why STEs can have such beneficial effects. We end by looking at the factors that might need to be considered if STEs are going to be practically implemented as a means of achieving ecological wellbeing.
... The history of LSD as a treatment for alcoholism goes back to 1953, when psychiatrists Humphry Osmond and Abram Hoffer introduced the drug to individuals with history of chronic alcohol use, testing the hypothesis that its capacity to help individuals achieve expanded levels of self-awareness could have therapeutic benefits [48] . In a small pilot experiment, two patients received a single dose of 200 μg LSD; one patient stopped drinking immediately after the treatment and remained sober for 6 months, and the other quit drinking during the follow-up period [48] . ...
... The history of LSD as a treatment for alcoholism goes back to 1953, when psychiatrists Humphry Osmond and Abram Hoffer introduced the drug to individuals with history of chronic alcohol use, testing the hypothesis that its capacity to help individuals achieve expanded levels of self-awareness could have therapeutic benefits [48] . In a small pilot experiment, two patients received a single dose of 200 μg LSD; one patient stopped drinking immediately after the treatment and remained sober for 6 months, and the other quit drinking during the follow-up period [48] . ...
Full-text available
Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction has been noted as the last stage of a chronic disease that may impair brain reward circuit responses and affects personal and social life. Treatments for SUD face challenges including availability and limited pharmacological response, often resulting in low retention of patients. A growing number of studies from the 'psychedelic renaissance' have highlighted the therapeutic potential of psychedelics for several psychiatric disorders, including SUD. In this non-systematic review we discuss past and current clinical and observational studies with classic (LSD, DMT, psilocybin and mescaline) and non-classic (ibogaine, ketamine, MDMA, salvinorin A and THC) psychedelics for the treatment of SUD published until December 2021. Although results are still inconclusive for LSD, DMT, mescaline, MDMA and Salvinorin A, in general, the literature presents moderate evidence on the controlled use of psilocybin and ketamine for Alcohol Use Disorder, ketamine for management of opiate and alcohol withdrawal, and THC preparations for reducing withdrawal symptoms in Cannabis and possibly in Opioid Use Disorder. Importantly, studies suggest that psychedelics should be more effective when employed as an adjunct therapy. Extensive research is warranted to further elucidate the role of psychedelics in the treatment of SUD.
... The search for more efficient pharmacotherapies to reduce alcohol intake has led scientists to look into psychedelics (Bogenschutz, 2013). Interest in psychedelics, compounds with mixed serotonin receptor agonist actions, such as psilocybin or lysergic acid diethylamide (LSD) as potential therapeutics for psychiatric disorders, has re-emerged during the last decade (Carhart-Harris and Goodwin, 2017), but the idea of using them to treat problematic alcohol use has its roots in 1950s (Dyck, 2006). A recent meta-analysis investigated these earlier clinical studies and, based on the results of six randomized studies with more than 500 participants, reported that a single dose of LSD is associated with reductions in alcohol misuse lasting even up to 12 months (Krebs and Johansen, 2012). ...
Full-text available
Abstract Background: Psychedelics, like lysergic acid diethylamide (LSD), are again being studied as potential therapies for many neuropsychiatric disorders, including addictions. At the same time, the acute effects of psychedelics on rewarding behaviours have been scarcely studied. Aims: The current study aimed to clarify if LSD decreases binge-like ethanol drinking in mice, and whether the observed acute effects on ethanol consumption are generalizable to a natural reinforcer, sucrose, and if the effects resulted from aversive or reward-attenuating effects caused by LSD. Methods: The effects of acute LSD were examined using 2-bottle choice intermittent ethanol (20%) and sucrose drinking (10%), discrete-trial current-intensity threshold method of intracranial self-stimulation and short-term feeding behaviour assay in C57BL/6 male mice. Results: The results showed that acute 0.1 mg/kg, but not 0.05 mg/kg, dose (i.p.) of LSD reduced 2-h intermittent ethanol drinking transiently without any prolonged effects. No effects were seen in intermittent 2-h sucrose drinking. The tested LSD doses had neither effect on the intracranial self-stimulation current-intensity thresholds, nor did LSD affect the threshold-lowering, or rewarding, effects of simultaneous amphetamine treatment. Furthermore, LSD had small, acute diminishing effects on 2-h food and water intake. Conclusions: Based on these results, LSD decreases binge-like ethanol drinking in mice, but only acutely. This effect is not likely to stem from reward-attenuating effects but could be in part due to reduced consummatory behaviour.
... The first synthetic psychedelic known to the Western world was LSD. There was a period of extensive research with suboptimal methodologies in the 1950s and 1960s into the use of classic psychedelics for the treatment of anxious and depressive disorders, substance use disorders, functional neurological disorders, and distress in terminal cancer, with results that (albeit clinician-judged) were often encouraging (Butler et al., 2020;Dyck, 2006;Grof and Halifax, 1977;Rucker et al., 2016;Weston et al., 2020). However, LSD, in particular, diffused from the clinic into recreational use. ...
Full-text available
Background Postpartum depression (PPD) is a major public health concern and has, at its core, a sense of maternal ‘disconnection’ – from the self, the infant, and the support system. While PPD bears similarities with MDD, there is increasing evidence for its distinct nature, especially with the unique aspect of the mother-infant relationship. Current treatment modalities for PPD, largely based on those used in major depressive disorder (MDD), have low remission rates with emerging evidence for treatment resistance. It is, therefore, necessary to explore alternative avenues of treatment for PPD. Objective In this narrative review, we outline the potential therapeutic rationale for serotonergic psychedelics in the treatment of PPD, and highlight safety and pragmatic considerations for the use of psychedelics in the postpartum period. Methods We examined the available evidence for the treatment of PPD and the evidence for psychedelics in the treatment of MDD. We explored safety considerations in the use of psychedelics in the postpartum period. Results There is increasing evidence for safety, and encouraging signals for efficacy, of psilocybin in the treatment of MDD. Psilocybin has been shown to catalyse a sense of ‘reconnection’ in participants with MDD. This effect in PPD, by fostering a sense of ‘reconnection’ for the mother, may allow for improved mood and maternal sensitivity towards the infant, which can positively impact maternal role gratification and the mother-infant relationship. Conclusion Psychedelic assisted therapy in PPD may have a positive effect on the mother-infant dyad and warrants further examination.
... For example, the previously popular, and sometimes still used, label hallucinogen is considered less accurate and potentially misleading when referring to these drugs given that not all effects of 5-HT2AR agonists are strict hallucinations or confined to perceptual effects alone. Presently, the term psychedelic, first coined by Humphrey Osmond in 1957 referring to the class of drugs that he considered "mind-manifesting," is considered preferred by many given its suggestion of a class of compounds that produce more general, non-ordinary forms of consciousness and/or altered states of self upon use (Dyck, 2006). ...
The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an overview of the human behavioral pharmacology of psychedelics focusing on three prototypic classic psychedelics—psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT). A brief historical overview of the classic psychedelics and naming and drug classification is first specified. Next, special considerations in the conduct of human behavioral pharmacology work with psychedelics is described including the role of set and setting, mystical experience measurement, the use of effective blinding and placebos, and the abuse liability of psychedelics. Following, a description of the subjective, physiological, and clinical effects of psilocybin, LSD, and DMT is provided. This body of work clearly documents a unique and complex collection of subjective effects following psychedelic use, both during acute drug administration and as related to long-term behavior change following use. Clinical research demonstrates potential therapeutic utility with early phase clinical trials showing positive and enduring effects in many difficult-to-treat conditions including treatment-resistant depression, alcohol use disorder, and cigarette smoking. Future work in this newly reemerged field is needed to reveal mechanisms of behavior change in psychedelic drug action. Behavioral pharmacology is ultimately well served to provide this direction answering questions at the intersection of environment and pharmacology.
Full-text available
Introduction: Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly meaningful experiences that may spur a positive change in drinking behaviour when administered in a therapeutic context. However, the efficacy of a single psilocybin administration and its potential neurobiological underpinnings still remain unknown. Methods and analysis: To establish efficacy, we will investigate the effects of psilocybin-assisted therapy versus placebo in a randomised, double-blinded, placebo-controlled 12-week clinical trial. Ninety treatment-seeking patients, aged 20-70 years, diagnosed with alcohol use disorder will be recruited from the community via advertisement and referrals from general practitioners or specialised treatment units. The psilocybin or placebo will be administered in accordance with a protocol for psychological support before, during and after the dosing. Outcome assessments will be carried out 1, 4, 8 and 12 weeks postdosing. The primary outcome is reduction in the percentage of heavy drinking days from baseline to follow-up at 12 weeks. Key secondary outcomes are as follows: (1) total alcohol consumption, (2) phosphatidyl-ethanol, an objective biomarker for alcohol, (3) plasma psilocin, the active metabolite, to establish a possible therapeutic range, (4) the acute subjective drug experience as a possible predictor of treatment outcome and (5) neuronal response to alcohol cues and cognitive flexibility within corticostriatal pathways by use of functional MR brain imaging 1-week postdosing. Ethics and dissemination: Ethical approval has been obtained from the Committee on Health Research Ethics of the Capital Region of Denmark (H-20043832). All patients will be provided oral and written information about the trial before screening. The study results will be disseminated by peer-review publications and conference presentations. Trial registration number: EudraCT 2020-000829-55 and NCT05416229.
Full-text available
Here we consider psychedelics with respect to their mechanisms of action, use, and implications for our understandings of brain and mind. This review is somewhat nontraditional in its scope, with discussions of both basic facts as well as theoretical speculations. We chose this approach given the unique historical context we find ourselves in at present. While we have decades of investigations to draw upon with respect to the clinical science and neuropsychopharmacology of psychedelics, we are also witnessing a renaissance (or perhaps a revolution) in which scientific and public interest in these compounds seems to be exploding. We have decided to split this review between the fundamental and theoretical, with hopes that we can give readers familiarity with well-established knowledge, as well as questions to hold in mind in attempting to make sense of a rapidly shifting epistemic landscape. Below we focus on serotonin 2A receptor (5-HT2aR) agonists, or “classic psychedelics,” and discuss research suggesting their potential roles in clinical and non-clinical contexts. Particular emphasis is placed on studies suggesting potentially surprising degrees of efficacy for conditions such as depression and addictive disorders. We also evaluate potential mediators and moderators of therapeutic outcomes, including factors such as mystical experiences and psychological flexibility. Finally, we consider likely future directions for psychedelics in science and society.
Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. Classical psychedelics have a rich history and some of these compounds have been used in shamanic and spiritual ceremonies for millennia. The psychoactive effects of these drugs, particularly on human consciousness, have generated great scientific curiosity, and early research on psychedelics suggested their clinical benefits for psychiatric conditions, including alcohol use disorders and anxiety and depressive symptoms in terminal illness and life-threatening conditions. Since the 1990s, after a period of dormancy that followed the criminalization of psychedelic drugs since the Controlled Substance Act of 1970, the continued interest in their unique psychoactive effects along with the pursuit for novel and more effective treatments in psychiatry have led to a renewed interest in research on these compounds. While preliminary findings on psychedelics are encouraging, current evidence is still insufficient to support extensive use of these drugs routinely. Long-term safety and efficacy of these compounds remain unclear, and several clinical trials are underway and may add clarity to these questions. Therefore, this article intends to provide an overview of the evidence to date on psychedelic drugs – particularly psilocybin, MDMA, and LSD – for the treatment of psychiatric disorders.
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about ceremonial use of classic psychedelics and epidemiological studies that are consistent with anti-addiction efficacy. I review modern research using psilocybin in the treatment of alcohol use disorder and tobacco use disorder. Both lines of research show high success rates in preliminary studies. General anti-addiction efficacy across a variety of classes of addictive drugs is consistent with the notion that the persisting positive behavior change prompted by psychedelic therapy is due to amplification of psychotherapeutic processes. Future research should examine classic psychedelic treatment of additional substance use disorders including for opioids, cocaine, methamphetamine, and cannabis, and other disorders broadly characterized as addictions (e.g., obesity, problem gambling, hypersexual disorder). Future research should also explore addiction treatments with other classic psychedelics including LSD, mescaline, DMT, 5-MeO-DMT, and yet-to-be-discovered compounds. Experimental research is also needed to test different protocols for the delivery of classic psychedelic therapy for addictions. Given the staggering society costs of substance use disorders, including the mortality caused by tobacco smoking, it is critical that public funding be made available for scientists to follow up on promising early findings of classic psychedelics in addiction treatment. The costs and risks of not conducting such research are too great.
Full-text available
The concept of addiction is historically and culturally specific, becoming a common way of understanding experience first in early nineteenth-century America. This paper considers the relation to the concept of elements in current professional definitions of addiction (as dependence). Addiction concepts have become a commonplace in storytelling, offering a secular equivalent for possession as an explanation of how a good person can behave badly, and as an inner demon over which a hero can triumph.
The rise of the asylum constitutes one of the most profound, and controversial, events in the history of medicine. Academics around the world have begun to direct their attention to the origins of the confinement of those deemed 'insane', exploring patient records in an attempt to understand the rise of the asylum within the wider context of social and economic change of nations undergoing modernisation. Originally published in 2003, this edited volume brings together thirteen original research papers to answer key questions in the history of asylums. What forces led to the emergence of mental hospitals in different national contexts? To what extent did patient populations vary in terms of their psychiatric profile and socio-economic background? What was the role of families, communities and the medical profession in the confinement process? This volume therefore represents a landmark study in the history of psychiatry by examining asylum confinement in a global context.
This year marks the 50th anniversary of the original publication of Alcoholics Anonymous, the basic text for that mutual self-help organization devoted to helping alcoholics recover. The first edition was greeted with skepticism by the medical community1,2 based on the optimistic and spiritual writing style and the medical community's poor track record for alcoholism treatment.The ensuing 50 years have witnessed the development of Alcoholics Anonymous (AA) into the largest treatment program for alcoholics in the world. Health care providers now routinely turn to AA for help, referring alcoholics for the round-the-clock, round-the-calendar support and outreach that has helped them recover for brief and extended periods. Alcoholics Anonymous has proved itself to be a major feature of the diverse alcoholism treatment network that has emerged following the 1971 Hughes Act. We have incorporated it into our treatment planning, yet most of us (including specialists in alcoholism and addiction) have
In 1972, Phyllis Chester framed an indictment of American psychiatrists: "They are more willing to pity women than to respect them; more comfort- able with unhappy women than with angry women" (246). She offered this judgment in her book Women and Madness (1972), an angry and path- breaking reassessment of women's relation to the psychological "helping professions." Chesler invoked the fates of women, some famous (Zelda Fitzgerald, Sylvia Plath), some not so famous (Elizabeth Packard, Ellen West), who had sought or been forced to seek psychological assessment and treatment, and who, in the course of "treatment," had been physically, emotionally, and/or sexually abused within interlocking "mental health" systems powered by male-determined constructions of female roles and capacities. When women came up against psychiatry, Chesler asserted, women lost.
No effective answers have been gained for the questions "why do alcoholics drink so much," "why can't they stop drinking" or "why can't they learn to drink moderately?" Formulators of such questions have failed to de fine the key word in these questions—drink. Drinking is defined according to a well-established system of knowledge. Then the actions of the alcoholic are compared to this defined behavior system. The two are discovered to be anti thetical rather than similar, or, as some insist, identical. Application of this knowledge to some typical problem situations is suggested.